WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, March 02, 2007

Hide?	Set Name	Query	Hit Count
		DB=EPAB,JPAB,DWPI; PLUR=YES; OP=OR	
☐	L2	(inositol adj 1 adj 4 adj 5 adj trisphosphate adj 3 adj kinase or ITPKC) and apoptosis	0
		DB=PGPB,USPT; PLUR=YES; OP=OR	
☐	L1	(inositol adj 1 adj 4 adj 5 adj trisphosphate adj 3 adj kinase or ITPKC) and apoptosis	4

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 30	Feb 26	MEDLINE reloaded with enhancements
NEWS 31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS 32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
 NEWS X25       X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:40:25 ON 02 MAR 2007

=> file medline embase biosis caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:40:57 ON 02 MAR 2007

FILE 'EMBASE' ENTERED AT 16:40:57 ON 02 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:40:57 ON 02 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 16:40:57 ON 02 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (inositol(w)1(w)4(w)5(w)trisphosphate(w)3(w)kinase or ITPKC) and apoptosis
L1          22 (INOSITOL(W) 1(W) 4(W) 5(W) TRISPHOSPHATE(W) 3(W) KINASE OR
               ITPKC) AND APOPTOSIS

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2           22 DUP REM L1 (0 DUPLICATES REMOVED)

=> dis ibib abs l2

L2   ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:117791  CAPLUS
DOCUMENT NUMBER:          146:203915
TITLE:                    Gene expression profile for diagnosing small cell lung
                          cancer, discriminating from non-small cell lung
                          cancer, and assessing chemotherapy-resistant lung
                          cancer
INVENTOR(S):              Nakamura, Yusuke; Daigo, Yataro; Nakatsuru, Shuichi
PATENT ASSIGNEE(S):       Oncotherapy Science, Inc., Japan; The University of
                          Tokyo
SOURCE:                   PCT Int. Appl., 215pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
```

WO 2007013665 A2 20070201 WO 2006-JP315254 20060726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2005-703192P P 20050727
US 2006-799961P P 20060511

AB Methods for detecting and diagnosing small cell lung cancer (SCLC) are described. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histol. types of lung cancer, i.e., non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer, and methods for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy-resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or mol. targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected.

=> dis ibib abs l2 2-22

L2 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1278836 CAPLUS
DOCUMENT NUMBER: 146:55488
TITLE: Use of gene expression profiling to identify antiinflammatory macrolides
INVENTOR(S): Fanton, Christie; Mackichan, Mary Lee; Nakazawa, Kiyoshi; Uchida, Daisuke
PATENT ASSIGNEE(S): Chiron Corporation, USA; Taisho Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 208pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006130128	A2	20061207	WO 2005-US5401	20050218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-545177P P 20040218

AB The invention relates to the screening and selection of macrolide compds. for use as anti-inflammatory agents. The screening and selection of anti-inflammatory macrolides is based on the differential expression of one or more genes involved in the inflammatory process. Responses of A549 and THP-1 cells to clarithromycin and FMA 9045 were used to identify informative genes.

L2 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:795802 CAPLUS

DOCUMENT NUMBER: 145:246606

TITLE: Marker genes for the diagnosis of chronic fatigue syndrome by gene expression profiling

INVENTOR(S): Gow, John; Chaudhuri, Abhijit

PATENT ASSIGNEE(S): The University Court of the University of Glasgow, UK

SOURCE: PCT Int. Appl., 169pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082390	A1	20060810	WO 2006-GB332	20060201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2005-2042 A 20050201

AB Genes that show changes in levels of expression in chronic fatigue syndrome (myalgic encephalitis) are identified for use in the diagnosis of the disease and in its treatment. These genes include those encoding defensin α1, Hb γ, CXCR4, tubulin β1, serine/threonine kinase 17B, HLA-DRβ4, and prostaglandin D2 synthase. There is a relatively small set of genes, identified as a hub set, that show changes in expression that result in changes in levels of expression of a number of dependent or network genes. The genes identified provide objective disease markers that may be used in diagnostic tests to support the diagnosis of CFS/ME or for monitoring the effectiveness of therapy. They also provide a rational basis for classifying CFS/ME patients according to the biochem. lesion underlying their symptoms and enable provision of appropriate targeted therapies.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:191859 CAPLUS

DOCUMENT NUMBER: 144:252185

TITLE: Gene expression profiles in peripheral blood mononuclear cells in determination of the nature and severity of stroke

INVENTOR(S): Baird, Alison E.; Moore, David F.; Goldin, Ehud

PATENT ASSIGNEE(S): The Gov. Of the U.S.A as Represented by the Secretary of the Dept. Of Health & Human Services, USA
SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of Appl. No. PCT/US05/018744.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006046259	A1	20060302	US 2005-155835	20050617
WO 2005116268	A2	20051208	WO 2005-US18744	20050527
WO 2005116268	A3	20061214		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-575279P P 20040527
WO 2005-US18744 A2 20050527

AB A method for rapid and accurate diagnosis of the nature and severity of a stroke by measuring gene expression in peripheral blood mononuclear cells is described. Early diagnosis can be used to predict and prevent possible complications. The genes showing altered levels of expression include those associated with white blood cell activation and differentiation; in response to hypoxia, in vascular repair, and those related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related mol.

L2 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1291789 CAPLUS
DOCUMENT NUMBER: 144:46156
TITLE: Differential expression of molecules associated with acute stroke
INVENTOR(S): Baird, Alison E.; Moore, David F.; Goldin, Ehud
PATENT ASSIGNEE(S): United States Dept. of Health, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116268	A2	20051208	WO 2005-US18744	20050527
WO 2005116268	A3	20061214		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005248410	A1	20051208	AU 2005-248410	20050527
CA 2572795	A1	20051208	CA 2005-2572795	20050527
EP 1753881	A2	20070221	EP 2005-780084	20050527
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 2006046259	A1	20060302	US 2005-155835	20050617
PRIORITY APPLN. INFO.:			US 2004-575279P P	20040527
			WO 2005-US18744 W	20050527

AB Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurol. recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment.

L2 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:902703 CAPLUS
DOCUMENT NUMBER:	143:272498
TITLE:	Gene expression profiles in the diagnosis and treatment of Alzheimer's disease
INVENTOR(S):	Landfield, Philip W.; Porter, Nada M.; Chen, Kuey Chu; Geddes, James; Blalock, Eric
PATENT ASSIGNEE(S):	University of Kentucky Research Foundation, USA
SOURCE:	PCT Int. Appl., 114 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076939	A2	20050825	WO 2005-US3668	20050209
WO 2005076939	A3	20060706		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2004-542281P P	20040209

AB Genes showing altered patterns of expression in the brain that are associated with the neurol. changes found in Alzheimer's disease and that can be used in the early diagnosis of the disease, including the incipient form of the disease, are identified. The methods and kits of the invention utilize a set of genes and their encoded proteins that are shown to be correlated

with incipient Alzheimer's disease.

L2 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:732568 CAPLUS
DOCUMENT NUMBER: 143:206374
TITLE: Inositol 1,4,5 -trisphosphate 3-kinases (ITPKs) as modifiers of the insulin-like growth factor receptor (IGFR) pathway, screening for IGFR pathway modulators, and diagnostic and therapeutic uses thereof
INVENTOR(S): Friedman, Lori; Francis-Lang, Helen; Parks, Annette L.; Shaw, Kenneth James; Bjerke, Lynn Margaret; Heuer, Timothy S.
PATENT ASSIGNEE(S): Exelixis, Inc, USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072475	A2	20050811	WO 2005-US3560	20050127
WO 2005072475	A3	20051229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005209002	A1	20050811	AU 2005-209002	20050127
CA 2555381	A1	20050811	CA 2005-2555381	20050127
EP 1709445	A2	20061011	EP 2005-722736	20050127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				

PRIORITY APPLN. INFO.: US 2004-539837P P 20040128
WO 2005-US3560 W 20050127

AB The inventors discovered genes that modify the insulin-like growth factor receptor (IGFR) pathway in Drosophila using a dominant loss of function screen, and identified inositol 1,4, 5-trisphosphate 3- kinase (ITPK) genes as their human orthologs. Thus, human genes for ITPK isoforms are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function and/or ITPK function. Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of ITPK are provided. Preferred ITPK-modulating agents specifically bind to ITPK polypeptides and restore IGFR function. Other preferred ITPK-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress ITPK gene expression.

L2 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:673420 CAPLUS
DOCUMENT NUMBER: 143:167623
TITLE: Expression profiles of endothelial cells in response to TNF-α, IL-1β, and IL-8, methods of

assessing a tissue inflammatory response using the same, and diagnostic and therapeutic uses
INVENTOR(S): Smith, Steven Kevin; Charnock-Jones, David Stephen; Print, Cristin Gregor; Johnson, Nicola Anne
PATENT ASSIGNEE(S): Cambridge University Technical Services Limited, UK
SOURCE: PCT Int. Appl., 492 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068655	A2	20050728	WO 2005-GB57	20050114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005205218	A1	20050728	AU 2005-205218	20050114
CA 2551677	A1	20050728	CA 2005-2551677	20050114
GB 2424947	A	20061011	GB 2006-15106	20050114
EP 1711630	A2	20061018	EP 2005-701827	20050114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRIORITY APPLN. INFO.: GB 2004-976 A 20040116
WO 2005-GB57 W 20050114

AB The invention provides methods of assessing a tissue inflammatory response, comprising making a quant. determination of the level of at least five transcripts shown in transcriptome provided in the invention or proteins encoded thereby, in a sample; and comparing the abundance of said transcripts or proteins so determined with the level of said transcript obtained from a control sample. Methods for diagnosis of a condition with which a tissue inflammatory response is associated are also provided, as are gene chip arrays and protein based assays suitable for use in these methods. Assay methods for determining a modulator of a tissue inflammatory response or a condition associated therewith also form part of the invention. The gene expression was profiled in human umbilical vein endothelial cells (HUVEC) contacted with a mixture of TNF-α, interleukin-1β, and interleukin-8. In addition, expression in different endothelial cells types obtained from different parts of the body, namely HUVEC, human coronary artery endothelial cells (HCAEC) and human uterine microvascular endothelial cells (UtMVEC) were analyzed. It was found that many transcripts were consistently regulated by inflammatory signals in all three cell types.

L2 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:523313 CAPLUS
DOCUMENT NUMBER: 143:38415
TITLE: Biomarkers for the efficacy of calcitonin and parathyroid hormone analog treatment
INVENTOR(S): Bobadilla, Maria
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053731	A1	20050616	WO 2004-EP13347	20041124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004294268	A1	20050616	AU 2004-294268	20041124
CA 2546111	A1	20050616	CA 2004-2546111	20041124
EP 1689427	A1	20060816	EP 2004-819617	20041124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1905894	A	20070131	CN 2004-80040915	20041124
BR 2004016945	A	20070213	BR 2004-16945	20041124
PRIORITY APPLN. INFO.:			US 2003-525025P P	20031125
			WO 2004-EP13347 W	20041124

AB Gene expression assays were performed using tissues of monkeys treated with the calcitonin or parathyroid hormone analog (e.g., PTS 893) at sub-therapeutic dose. The assays were analyzed to identify the modes of actions of calcitonin or parathyroid hormone with relationships to therapeutic applications. Among the biomarkers are the expression profiles of the genes for Y-box binding protein, bone morphogenetic proteins, fibroblast growth factors, insulin-like growth factors, vascular endothelial growth factor, α-2-HS glycoprotein, osteoclast stimulating factor, nuclear receptors (steroid/thyroid family), and others. The results obtained support the anabolic effect of salmon calcitonin on bone metabolism

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:447673 CAPLUS
DOCUMENT NUMBER: 143:20875
TITLE: Differentially expressed gene profile for diagnosing and treating mental disorders
INVENTOR(S): Akil, Huda; Atz, Mary; Bunney, William E., Jr.; Choudary, Prabhakara V.; Evans, Simon J.; Jones, Edward G.; Li, Jun; Lopez, Juan F.; Myers, Richard; Thompson, Robert C.; Tomita, Hiroaki; Vawter, Marquis P.; Watson, Stanley
PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior University, USA
SOURCE: PCT Int. Appl., 226 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046434	A2	20050526	WO 2004-US36784	20041105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005209181	A1	20050922	US 2004-982556	20041104
AU 2004289247	A1	20050526	AU 2004-289247	20041105
CA 2543811	A1	20050526	CA 2004-2543811	20041105
EP 1680009	A2	20060719	EP 2004-800741	20041105

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU

PRIORITY APPLN. INFO.:	US 2003-517751P	P	20031105
	US 2004-982556	A	20041104
	WO 2004-US36784	W	20041105

AB The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The present invention uses DNA microarray anal. to demonstrate differential expression of genes in selected regions of post-mortem brains from patients diagnosed with mental disorders in comparison with normal control subjects. The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

L2 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:158474 CAPLUS
DOCUMENT NUMBER:	142:254569
TITLE:	Derivatives of cyclic quinone that regulate gene expression for use in prevention or therapy of human diseases
INVENTOR(S):	Padia, Janak K.; O'Brien, Sean; Lu, Jiemin; Pikul, Stanislaw
PATENT ASSIGNEE(S):	Avalon Pharmaceuticals, USA
SOURCE:	PCT Int. Appl., 115 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016000	A1	20050224	WO 2004-US25038	20040803

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2003-492653P	P	20030805
OTHER SOURCE(S):	MARPAT 142:254569		

AB This invention relates to production of cyclic quinone derivs. for use in regulation of gene expression, as relates to prevention or therapy of human diseases. Cyclic quinone synthesis schemes and structures are

presented. With the goal of transcription regulation in diseased tissues, gene expression profile data is provided. The intended disease target for this invention is adenocarcinoma of the colon, however the invention claims application in numerous human diseases. Applications of the invention include production of cyclic quinone-based active ingredients in therapeutic agents.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:71066 CAPLUS
DOCUMENT NUMBER: 142:170050
TITLE: DEF domain-containing members of the MAP kinase pathway and their use in screening for drug inhibitors
INVENTOR(S): Blenis, John; Murphy, Leon O.
PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007090	A2	20050127	WO 2004-US21514	20040702

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-484761P P 20030703

AB Mitogen-activated protein (MAP) kinases (e.g., ERK1/2) phosphorylate a variety of target proteins including, for example, several immediate-early gene products (e.g., Fos, Myc, and Jun family proteins). Certain phosphorylation reactions require binding of the MAP kinase to the DEF domain of the target protein. Inhibitors that block this interaction may be useful therapeutics for human disease, including as antineoplastic agents. This invention provides several advantages over known therapies that directly target the MAP kinase signaling cascade. Typically, most compds. that inhibit the MAP kinase pathway are non-specific and inhibit more than one enzyme, and the targeted inhibited kinases are not available to perform normal physiol. functions necessary for cell survival, whereas therapeutic methods of the present invention inhibit the activation of particular target proteins and leave the MAP kinases enzymically active and available to phosphorylate other non-DEF domain-containing proteins. Thus, DEF domains are identified in a large number of proteins, and the principles of the invention are exemplified using the immediate-early gene, c-Fos. Screening assays useful for identifying compds. that inhibit the MAP kinase-DEF domain interaction are also disclosed.

L2 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:394682 CAPLUS
DOCUMENT NUMBER: 142:445550
TITLE: Gene expression profiles for the diagnosis and prognosis of breast cancer
INVENTOR(S): Erlander, Mark; Ma, Xiao-Jun; Wang, Wei; Wittliff, James L.

PATENT ASSIGNEE(S): Arcturus Bioscience, Inc. University of Louisville, USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005095607	A1	20050505	US 2004-795092	20040305
WO 2005098037	A1	20051020	WO 2004-US6760	20040305
WO 2005098037	A8	20060209		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1651772	A1	20060503	EP 2004-718019	20040305

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.:	US 2003-453006P	P 20030307
	WO 2004-US6760	W 20040305

AB The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of breast cancer patient populations with different survival outcomes. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or determination of the prognosis of a patient, including breast cancer survival.

L2 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:78074 CAPLUS
DOCUMENT NUMBER: 142:172874
TITLE: Apoptosis-related kinase/G protein-coupled receptors and their use in diagnosis and drug screening
INVENTOR(S): Seery, Liam; Hayes, Ian; Murphy, Finbarr
PATENT ASSIGNEE(S): Eirx Therapeutics Limited, Ire.
SOURCE: U.S. Pat. Appl. Publ., 264 pp., Cont.-in-part of U.S. Ser. No. 764,238.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005019746	A1	20050127	US 2004-781581	20040218
US 2004219616	A1	20041104	US 2004-764238	20040123

PRIORITY APPLN. INFO.:	GB 2003-1566	A	20030123
	US 2003-457533P	P	20030325
	US 2004-764238	A2	20040123

AB The present invention relates to methods of identifying an agent that modulates the function of an apoptosis-associated polypeptide. RNA interference (siRNA knockdown) in the neutrophil model of

apoptosis identify the following kinases and/or G protein-coupled receptors (GPCR) as having roles in apoptosis: MAK, GPR86, PCTAIRE, GRAF, MPSK1, RS6PK, TLK2, EK1, MKNK, NTKL, CDC42, RBSK, EDG6, PRK, MAPKK5, P14KB, FLT4, PSKH1, ITPKC, and ROCK. The invention also relates to methods of modulating apoptosis, diagnostic methods, arrays, kits and compns. based upon the apoptosis -associated polypeptides.

L2 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1020555 CAPLUS
DOCUMENT NUMBER: 143:320266
TITLE: Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ
INVENTOR(S): Ueda, Minoru; Yamada, Yoichi
PATENT ASSIGNEE(S): Hitachi Medical Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 246 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005253442	A	20050922	JP 2004-111582	20040309
PRIORITY APPLN. INFO.:			JP 2004-111582	20040309

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by 2>-fold, compared to hMSCs, was 614 (Table, IV). On the other band, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L2 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:905935 CAPLUS
DOCUMENT NUMBER: 141:389792
TITLE: Genes associated with cocaine addiction and their use in diagnosis and analysis of prospective drugs
INVENTOR(S): Hemby, Scott Edwards
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092417	A2	20041028	WO 2004-US10649	20040407
WO 2004092417	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-461019P P 20030407
US 2004-550467P P 20040305

AB The present invention provides compns. and methods useful in the diagnosis and treatment of addictive disorders including cocaine addiction. Target genes and their expression products are identified based on their differential expression in subjects affected by addictive disorders in comparison with control subjects. In another aspect, the invention also provides methods for evaluating candidate drugs to predict their therapeutic efficacy. The invention also provides methods for predicting whether a compound will be addictive. Compns. of the invention include arrays, computer-readable mediums, and kits for use in the methods of the invention.

L2 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:634161 CAPLUS
DOCUMENT NUMBER: 141:167758
TITLE: Sequences of apoptosis-associated protein kinases and G protein-coupled receptors, and use in cancer diagnosis, therapy, and drug screening
INVENTOR(S): Seery, Liam; Hayes, Ian; Murphy, Finbarr
PATENT ASSIGNEE(S): Eirx Therapeutics Limited, Ire.
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065959	A2	20040805	WO 2004-GB271	20040123
WO 2004065959	A3	20041125		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ

AU 2004205785	A1	20040805	AU 2004-205785	20040123
CA 2513148	A1	20040805	CA 2004-2513148	20040123
EP 1588163	A2	20051026	EP 2004-704638	20040123

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006518590	T	20060817	JP 2006-500235	20040123

PRIORITY APPLN. INFO.: GB 2003-1566 A 20030123
US 2003-457533P P 20030325
WO 2004-GB271 W 20040123

AB The present invention identifies a number of genes, "apoptosis -associated" genes, whose expression is correlated with an early stage in the regulation of apoptosis. The identification and role of these

genes in apoptosis is validated using model assays and by knocking down gene expression using RNAi and assessing the resultant phenotype for altered apoptosis progression. Accordingly, these genes represent new targets for therapeutic targets. Methods are provided for identifying agents that modulate the function of an apoptosis -associated polypeptide or expression of nucleic acids encoding the apoptosis-associated polypeptide, as well as detecting the presence of an apoptosis-associated polypeptide in a sample using hybridization-based levels of gene expression or antibody binding.

L2 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:355085 CAPLUS
DOCUMENT NUMBER: 140:369944
TITLE: Human tissue-specific housekeeping genes identified by expression profiling
INVENTOR(S): Aburatani, Hiroyuki; Yamamoto, Shogo
PATENT ASSIGNEE(S): NGK Insulators, Ltd., Japan
SOURCE: PCT Int. Appl., 372 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035785	A1	20040429	WO 2002-JP10753	20021016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002344094	A1	20040504	AU 2002-344094	20021016
US 2004229233	A1	20041118	US 2003-684422	20031015
PRIORITY APPLN. INFO.:			US 2002-418614P P	20021016
			WO 2002-JP10753 A	20021016

AB Housekeeping genes commonly expressed in 35 different human tissues, oligonucleotide probes and DNA microarrays containing them, are disclosed.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:401250 CAPLUS
DOCUMENT NUMBER: 141:22096
TITLE: Microarray Analysis Reveals Differences in Gene Expression of Circulating CD8+ T Cells in Melanoma Patients and Healthy Donors
AUTHOR(S): Xu, Tong; Shu, Chen-Tsen; Purdom, Elizabeth; Dang, Demi; Ilsley, Diane; Guo, Yaqian; Weber, Jeffrey; Holmes, Susan P.; Lee, Peter P.
CORPORATE SOURCE: Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
SOURCE: Cancer Research (2004), 64(10), 3661-3667
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Circulating T cells from many cancer patients are known to be dysfunctional and undergo spontaneous apoptosis. We used

microarray technol. to determine whether gene expression differences exist in T cells from melanoma patients vs. healthy subjects, which may underlie these abnormalities. To maximize the resolution of our data, we sort purified CD8+ subsets and amplified the extracted RNA for microarray anal. These analyses show subtle but statistically significant expression differences for 10 genes in T cells from melanoma patients vs. healthy controls, which were addnl. confirmed by quant. real-time PCR anal. Whereas none of these genes are members of the classical apoptosis pathways, several may be linked to apoptosis. To addnl. investigate the significance of these 10 genes, we combined them into a classifier and found that they provide a much better discrimination between melanoma and healthy T cells as compared with a classifier built uniquely with classical apoptosis-related genes. These results suggest the possible engagement of an alternative apoptosis pathway in circulating T cells from cancer patients.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:51660 CAPLUS
DOCUMENT NUMBER: 136:98853
TITLE: Proteins and nucleic acids associated with aging and their detection in identification of tissues undergoing senescence and of senescence modulators
INVENTOR(S): Burmer, Glenna; Pritchard, David; Brown, Joseph P.; Demas, Vasiliki
PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002004662	A1	20020117	WO 2001-US21361		20010703
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2001073208	A5	20020121	AU 2001-73208		20010703
US 2002098495	A1	20020725	US 2001-898730		20010703
PRIORITY APPLN. INFO.:			US 2000-216470P	P	20000706
			WO 2001-US21361	W	20010703

AB This invention relates to the discovery of nucleic acids and proteins associated with the aging processes, such as cell proliferation and senescence. The identification of these aging-associated nucleic acids and proteins have diagnostic uses in detecting the aging status of a cell population as well as applications for gene therapy and the delaying of the aging process.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:411495 CAPLUS
DOCUMENT NUMBER: 135:179631
TITLE: Profiling changes in gene expression during

differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics

AUTHOR(S): Le Naour, Francois; Hohenkirk, Lyndon; Grolleau, Annabelle; Misek, David E.; Lescure, Pascal; Geiger, James D.; Hanash, Samir; Beretta, Laura

CORPORATE SOURCE: Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, 48109-0666, USA

SOURCE: Journal of Biological Chemistry (2001), 276(21), 17920-17931
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Dendritic cells (DCs) are antigen-presenting cells that play a major role in initiating primary immune responses. The authors have utilized two independent approaches, DNA microarrays and proteomics, to analyze the expression profile of human CD14+ blood monocytes and their derived DCs. Anal. of gene expression changes at the RNA level using oligonucleotide microarrays complementary to 6300 human genes showed that .apprx.40% of the genes were expressed in DCs. A total of 255 genes (4%) were regulated during DC differentiation or maturation. Most of these genes were not previously associated with DCs and included genes encoding secreted proteins as well as genes involved in cell adhesion, signaling, and lipid metabolism Protein anal. of the same cell populations was done using two-dimensional gel electrophoresis. A total of 900 distinct protein spots were included, and 4% of them exhibited quant. changes during DC differentiation and maturation. Differentially expressed proteins were identified by mass spectrometry and found to represent proteins with Ca2+ binding, fatty acid binding, or chaperone activities as well as proteins involved in cell motility. In addition, proteomic anal. provided an assessment of post-translational modifications. The chaperone protein, calreticulin, was found to undergo cleavage, yielding a novel form. The combined oligonucleotide microarray and proteomic approaches have uncovered novel genes associated with DC differentiation and maturation and has allowed anal. of post-translational modifications of specific proteins as part of these processes.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:147332 CAPLUS

DOCUMENT NUMBER: 132:330417

TITLE: cDNA-RDA of genes expressed in fetal and adult lungs identifies factors important in development and function

AUTHOR(S): Cooper, Paul; Mueck, Beatrice; Yousefi, Shida; Potter, Suzanne; Jarai, Gabor

CORPORATE SOURCE: Molecular and Cell Biology Unit, Novartis Horsham Research Centre, Horsham, RH13 5AB, UK

SOURCE: American Journal of Physiology (2000), 278(2, Pt. 1), L284-L293
CODEN: AJPHAP; ISSN: 0002-9513

PUBLISHER: American Physiological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The identification of genetic factors important in lung development and function will help in understanding the underlying mol. mechanisms of respiratory disease. Representational difference anal. of cDNA (cDNA-RDA) is a PCR-based subtractive enrichment procedure for the isolation of differentially expressed genes. We performed cDNA-RDA and isolated genes expressed more abundantly in fetal and adult lungs. Fifty-four clones potentially representing genes with higher transcript levels in the fetal

lung were sequenced. Sequence similarity searches indicated that these clones included 12 known genes, a discoidin-like domain-containing gene, six expressed sequence tags (ESTs), and one novel sequence. Fifty-six clones potentially representing genes expressed more abundantly in the adult lung were also cloned and sequenced. Of these, 16 known human genes were represented along with two sequences significantly similar to known mouse genes and two novel sequences. Several of these known genes are implicated in stress response and lung protection. Thus cDNA-RDA was successfully used to isolate known and novel differentially expressed genes, which putatively play an important role in human lung development.

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	84.08	84.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-17.16	-17.16

FILE 'STNGUIDE' ENTERED AT 16:43:12 ON 02 MAR 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 23, 2007 (20070223/UP).

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 30	Feb 26	MEDLINE reloaded with enhancements
NEWS 31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS 32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
 NEWS X25       X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:35:10 ON 02 MAR 2007

=> file medline embase biosis caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 17:35:35 ON 02 MAR 2007

FILE 'EMBASE' ENTERED AT 17:35:35 ON 02 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:35:35 ON 02 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:35:35 ON 02 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (inositol(w)1(w)4(w)5(w)trisphosphate(w)3(w)kinase(w)C or ITPKC) and neutrophil
L1            1 (INOSITOL(W) 1(W) 4(W) 5(W) TRISPHOSPHATE(W) 3(W) KINASE(W) C
                OR ITPKC) AND NEUTROPHIL

=> dis ibib abs l1

L1  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:78074  CAPLUS
DOCUMENT NUMBER:          142:172874
TITLE:                    Apoptosis-related kinase/G protein-coupled receptors
                          and their use in diagnosis and drug screening
INVENTOR(S):              Seery, Liam; Hayes, Ian; Murphy, Finbarr
PATENT ASSIGNEE(S):       Eirx Therapeutics Limited, Ire.
SOURCE:                   U.S. Pat. Appl. Publ., 264 pp., Cont.-in-part of U.S.
                          Ser. No. 764,238.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2005019746         A1    20050127    US 2004-781581           20040218
     US 2004219616         A1    20041104    US 2004-764238           20040123
PRIORITY APPLN. INFO.:                       GB 2003-1566         A   20030123
                                             US 2003-457533P      P   20030325
                                             US 2004-764238       A2  20040123
AB   The present invention relates to methods of identifying an agent that
```

modulates the function of an apoptosis-associated polypeptide. RNA interference (siRNA knockdown) in the neutrophil model of apoptosis identify the following kinases and/or G protein-coupled receptors (GPCR) as having roles in apoptosis: MAK, GPR86, PCTAIRE, GRAF, MPSK1, RS6PK, TLK2, EK1, MKNK, NTKL, CDC42, RBSK, EDG6, PRK, MAPKK5, P14KB, FLT4, PSKH1, ITPKC, and ROCK. The invention also relates to methods of modulating apoptosis, diagnostic methods, arrays, kits and compns. based upon the apoptosis-associated polypeptides.